Search - tctmd.com

Displaying 101 - 120 of 386

Sort: Relevancy | Date

Presentation TCT 2019

Defining High Bleeding Risk: HBR ARC

Presenter: Philip Urban

September 27, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

The Low-Bleeding Risk Patient: Should DAPT be Tailored Based on Clinical Presentation, Anatomic Complexity or DES Type?

Presenter: Ajay Kirtane

September 26, 2019

Presentation TCT 2019

The High-Bleeding Risk Patient: Current Recommendations and Overview of Dedicated Trials

Presenter: Stephan Windecker

September 26, 2019

Presentation TCT 2019

Primer on Metallic Stents Developed in India

Presenter: Upendra Kaul

September 26, 2019

Presentation TCT 2019

Primer on Metallic Stents Developed in China

Presenter: Run-Lin Gao

September 26, 2019

Presentation TCT 2019

Pro-Healing Stents (With Active and Passive Coatings): Latest Clinical Evidence

Presenter: Robert de Winter

September 26, 2019

Presentation TCT 2019

Polymer-Free DES: Lessons Learned From Recent Trials

Presenter: Michael Maeng

September 26, 2019

Presentation TCT 2019

Biodegradable Polymer DES: Do Clinical Trial Data Support Claims of Superior Safety or Effectiveness?

Presenter: Takeshi Kimura

September 26, 2019

Presentation TCT 2019

The Case for Further Reducing Strut Thickness: Technical Challenges and Clinical Benefits

Presenter: Sripal Bangalore

September 26, 2019

Presentation TCT 2019

Impact of Stent Design Features on Vascular Healing and Surface Thrombogenicity: What Really Matters?

Presenter: Greg Kaluza

September 26, 2019

Opening Debate: Which Metallic DES Should Be on My Cath Lab Shelf? - Choose Carefully: The Best New Generation DES are Associated With Meaningful Improvements In Performance and Outcomes!

Presentation TCT 2019

Choose Carefully: The Best New Generation DES are Associated With Meaningful Improvements In Performance and Outcomes!

Presenter: David Kandzari

September 26, 2019

Opening Debate: Which Metallic DES Should Be on My Cath Lab Shelf? - Choose Whatever You Want! Most Contemporary DES Display Comparable Clinical Performance!

Presentation TCT 2019

Choose Whatever You Want! Most Contemporary DES Display Comparable Clinical Performance!

Presenter: Stephan Windecker

September 26, 2019

Presentation TCT 2019

Clinical Trial Snapshots: Top DES Randomized Trials of the Last 2 Years

Presenter: Mamas Mamas

September 26, 2019

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Caitlin E. Cox

September 20, 2019

Advertisement

Defining High Bleeding Risk: HBR ARC

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

The Low-Bleeding Risk Patient: Should DAPT be Tailored Based on Clinical Presentation, Anatomic Complexity or DES Type?

The High-Bleeding Risk Patient: Current Recommendations and Overview of Dedicated Trials

Primer on Metallic Stents Developed in India

Primer on Metallic Stents Developed in China

Pro-Healing Stents (With Active and Passive Coatings): Latest Clinical Evidence

Polymer-Free DES: Lessons Learned From Recent Trials

Biodegradable Polymer DES: Do Clinical Trial Data Support Claims of Superior Safety or Effectiveness?

The Case for Further Reducing Strut Thickness: Technical Challenges and Clinical Benefits

Impact of Stent Design Features on Vascular Healing and Surface Thrombogenicity: What Really Matters?

Choose Carefully: The Best New Generation DES are Associated With Meaningful Improvements In Performance and Outcomes!

Choose Whatever You Want! Most Contemporary DES Display Comparable Clinical Performance!

Clinical Trial Snapshots: Top DES Randomized Trials of the Last 2 Years

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content